title: HSP-70 as a nonspecific early marker in cisplatin ototoxicity.
abstract: CONCLUSIONS
  The great variety of pathological entities related to the presence of circulating HSP-70 suggests a nonspecific cellular damage. As the present study shows, positive results decrease with respect to the time elapsed after the injection of the ototoxic agent. HSP-70 appears as an early and transient marker that could permit early detection of inner ear damage.
  
  
  OBJECTIVE
  The aim of this study was to determine the presence of HSP-70 at different time points by means of Western blot immunoassay in the sera of rats treated with cisplatin.
  
  
  METHODS
  Thirty-six Wistar rats were intraperitoneally injected with cisplatin at a dose of 5 mg/kg and blood samples were collected at 7 and 90 days. Determination of HSP-70 was made by means of a modified Western blot immunoassay kit originally used for human HSP-70 antigen detection. A control group of 18 animals was used for comparison.
  
  
  RESULTS
  Western blot was positive in 77.8% of the animals in the 7 days group, decreasing to a 44.4% in the 90 days group. In the control group, Western blot was positive in 5.5%.
authors.affiliation: Ear Research Group, Department of Otorhinolaryngology, Hospital Universitario Puerta de Hierro, USA. atrinid@yahoo.es
authors.forename: R
authors.initials: R
authors.lastname: Ramírez-Camacho
authors.forename: M J
authors.initials: MJ
authors.lastname: Citores
authors.forename: A
authors.initials: A
authors.lastname: Trinidad
authors.forename: J M
authors.initials: JM
authors.lastname: Verdaguer
authors.forename: J R
authors.initials: JR
authors.lastname: García-Berrocal
authors.forename: A Martín
authors.initials: AM
authors.lastname: Marero
authors.forename: A
authors.initials: A
authors.lastname: Puente
authors.forename: J A
authors.initials: JA
authors.lastname: González-García
authors.forename: J A
authors.initials: JA
authors.lastname: Vargas
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000633:toxicity*; D015415:Biomarkers; D015153:Blotting, Western; D002945:Cisplatin / Q000009:adverse effects / Q000633:toxicity*; D003051:Cochlea / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D007758:Ear, Inner / Q000187:drug effects*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology; D050884:HSP72 Heat-Shock Proteins / Q000276:immunology / Q000378:metabolism*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D018840:HSP70 Heat-Shock Proteins; D050884:HSP72 Heat-Shock Proteins; C097210:Hspa1a protein, rat; D002945:Cisplatin